2018 Clinic Disease Radiation Oncology 
Imaging Technology
OCTOBER 3, 2023
2 poster presentation at the American Society for Radiation Oncology's (ASTRO) 65th Annual Meeting, ASTRO 2023 , being held this week in San Diego, CA. We could not have achieved these interim clinical results without the support of the doctors and patients who were part of this registry study from across the nation," said Brachman.
AuntMinnie
MARCH 26, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. After binding to the receptor, the drug works by entering the cell allowing radiation to cause damage to the tumor cells.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Imaging Technology
OCTOBER 5, 2023
Effective initial staging of prostate cancer, particularly with regards to the detection of metastatic disease, is critical to optimal clinical management of patients,” said Phillip H. Such information can help guide treatment selection and potentially avoid futile surgery for patients with high-risk disease.” “We
AuntMinnie
JUNE 20, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. After binding to the receptor, the drug works by entering the cell allowing radiation to cause damage to the tumor cells.
AuntMinnie
JANUARY 31, 2024
In data from a phase III clinical trial, the investigators found that gallium-68 (Ga-68) PSMA-11 PET initiated major management changes to salvage radiotherapy (RT) planning in 33% of patients – notably, a group for whom the technique was first approved in the U.S.
Expert insights. Personalized for you.
122 
Let's personalize your content